A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection.

Background: DAS181, a novel host-directed antiviral in development for influenza treatment, was assessed in this phase II clinical trial.

Methods: This study was a double-blind, placebo-controlled phase II clinical trial assessing influenza viral load and patient safety in otherwise healthy influenza-infected participants. Participants were randomized to a single-dose, multiple-dose, or placebo group and were followed for safety and virologic outcomes.